Replimune Group, INC Form 4 insider transactions

Replimune Group, Inc.'s Chief Accounting Officer, Andrew Schwendenman, is scheduled to receive a grant of 10,000 restricted stock units on December 19, 2025, which will vest over two years.

Replimune Group, Inc. director Kapil Dhingra exercised stock options and immediately sold the acquired common stock.

Replimune Group, Inc. CEO Sushil Patel sold 10,000 shares of common stock for a weighted average price of $11.13 per share under a pre-arranged trading plan.

Replimune Group's Chief Commercial Officer, Christopher Sarchi, sold 5,208 shares of common stock to cover tax withholding obligations related to RSU vesting.

Replimune Group's Chief Medical Officer, Konstantinos Xynos, sold 7,248 shares of common stock at a weighted average price of $9.10 to cover tax withholding obligations related to RSU vesting.

Replimune Group's Chief Financial Officer, Emily Luisa Hill, sold 9,154 shares of common stock at $5.37 per share to cover tax withholding obligations related to RSU vesting.

Director Philip Astley-Sparke sold 32,279 shares of Replimune Group, Inc. to cover tax withholding obligations related to the vesting of restricted stock units.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 7,952 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Andrew Schwendenman, Chief Accounting Officer of Replimune Group, sold 3,287 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Replimune Group, Inc.'s CEO, Sushil Patel, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

Emily Luisa Hill, CFO of Replimune Group, sold 2,535 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Christopher Sarchi, Chief Commercial Officer of Replimune Group, sold shares to cover tax withholding obligations related to the vesting of restricted stock units.

A director of Replimune Group, Inc. acquired stock options exercisable for 32,000 shares of common stock.

CEO of Replimune Group, Sushil Patel, reports acquisition of common stock and stock options.

Director Paolo Pucci reports acquisition of stock options in Replimune Group, Inc.

Madhavan Balachandran, a director at Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., reports acquisition of stock options and restricted stock units.

Director Kapil Dhingra acquired stock options in Replimune Group, Inc. exercisable for 32,000 shares of common stock.

Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025.

Chief Financial Officer of Replimune Group, Emily Luisa Hill, reports the acquisition of common stock and stock options.

Director Dieter Weinand of Replimune Group, Inc. reports acquisition of stock options.

Christopher Sarchi, Chief Commercial Officer of Replimune Group, reports the acquisition of 45,000 shares of common stock and options to purchase 67,500 shares.

Christy J. Oliger, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025, at an exercise price of $8.40.

Andrew Schwendenman, Chief Accounting Officer of Replimune Group, reports acquisition of shares and stock options.

Baker Bros. Advisors reported changes in beneficial ownership of Replimune Group, Inc. due to the grant of non-qualified stock options to Michael Goller, a director by deputization.

Replimune's CEO, Sushil Patel, sold 10,000 shares of common stock at an average price of $12.42, as part of a pre-arranged trading plan.

Konstantinos Xynos, Chief Medical Officer of Replimune Group, sold 7,246 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Replimune Group's Chief Commercial Officer, Christopher Sarchi, sold 5,207 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Madhavan Balachandran, a director at Replimune Group, Inc., acquired stock options for 64,000 shares on September 4, 2024.

Philip Astley-Sparke, Executive Chairman of Replimune Group, disposed of 50,000 shares of common stock as a gift on August 30, 2024.